Who is eligible for clinical trial NCT06872333?

Participants must meet the protocol's inclusion criteria for Graft Failure. The stated age range is Not specified to 55 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06872333 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-01

Allo HSCT for High Risk Hemoglobinopathies (NCT06872333)

Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Masonic Cancer Center, University of Minnesota

🩺 Plain-English Summary (8th-Grade Level)

A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (7 items).

Location: Masonic Cancer Center — Minneapolis, Minnesota

Age range: Not specified to 55 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Sickle Cell Disease (SCD)
SCD Patients with a fully matched sibling donor (MSD) irrespective of the frequency or severity of symptoms MSD transplant can be considered. Parents/patient must be counseled as to the risks and benefits and provide their voluntary informed consent
Transfusion Dependent Alpha- or Beta- Thalassemia
Diamond Blackfan Anemia
Other Non-Malignant Hematologic Disorders
Karnofsky ≥ 60%, Lansky play score ≥ 60. Patients with lower performance score can be considered based on study team's evaluation.
Sexually active persons of childbearing potential or persons with partners of childbearing potential must agree to use a highly effective form of contraception during study treatment and for at least 4 months after the transplant.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Pregnant, breastfeeding or intending to become pregnant during the study. Persons of childbearing potential must have a negative pregnancy test (serum or urine) within 30 days of the start of treatment
HIV infection with a detectable viral load. All HIV+ patients must be evaluated by infectious disease (ID) and an HIV management plan established prior to transplantation.
Active, uncontrolled infection - infection that is stable or improving after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections) will be permitted
Known allergy to any of the study components
Psychiatric illness/social situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements
Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Masonic Cancer Center — Minneapolis, Minnesota

📞 Contact the Study Coordinator

Phone: (612) 626-2961

Email: gupta461@umn.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Graft Failure

CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure — New York, New York

Explore by condition: All Graft Failure clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗